Hosted on MSN1h
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...
If preliminary results were correct, simufilam could be the long-sought-after cure for dementia, the Holy Grail of ...
A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The ...
CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other ...
Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...
CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ...
CONTACT US HERE: ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam. Defendants’ statements ...
NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during ...
CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included ...
Cassava Sciences' Phase 3 RETHINK-ALZ trial for simufilam in Alzheimer's failed decisively, with the company discontinuing its second Phase 3 trial and reducing its workforce by 33%. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback